Advertisement
Advertisement

ADMA

ADMA logo

ADMA Biologics, Inc.

8.70
USD
Sponsored
+0.01
+0.12%
Jun 24, 16:00 UTC -4
Closed
exchange

After-Market

8.72

+0.03
+0.29%

ADMA Earnings Reports

Positive Surprise Ratio

ADMA beat 19 of 42 last estimates.

45%

Next Report

Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$134.99M
/
$0.18
Implied change from Q1 26 (Revenue/ EPS)
+17.90%
/
-5.26%
Implied change from Q2 25 (Revenue/ EPS)
+10.66%
/
+28.57%

ADMA Biologics, Inc. earnings per share and revenue

On May 06, 2026, ADMA reported earnings of 0.19 USD per share (EPS) for Q1 26, missing the estimate of 0.20 USD, resulting in a -6.86% surprise. Revenue reached 114.49 million, compared to an expected 145.27 million, with a -21.19% difference. The market reacted with a -15.97% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of 0.18 USD, with revenue projected to reach 134.99 million USD, implying an decrease of -5.26% EPS, and increase of 17.90% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, ADMA Biologics, Inc. reported EPS of $0.19, missing estimates by -6.86%, and revenue of $114.49M, -21.19% below expectations.
The stock price moved down -15.97%, changed from $10.08 before the earnings release to $8.47 the day after.
The next earning report is scheduled for Aug 04, 2026.
Based on 4 analysts, ADMA Biologics, Inc. is expected to report EPS of $0.18 and revenue of $134.99M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement